


Summary

It is therefore the object of the present disclosure to provide compounds, which bind to the orphan nuclear receptors ROR γ 1 and/or ROR γ t and, thus, to open new methods for treating diseases associated with the modulation of ROR γ , such as autoimmune diseases, inflammatory skin diseases or multiple sclerosis.

This object is solved by claims 1 to 24.

In a ~~one first~~ aspect of the present disclosure, there is provided a compound represented by Formula (1) to Formula (5)



an enantiomer, diastereomer, tautomer, *N*-oxide, solvate, formulation and pharmaceutically acceptable salt thereof,

wherein

R¹ is independently selected from C₁₋₁₀-alkyl, C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl, C₃₋₁₀-cycloalkyl, C₃₋₁₀-heterocycloalkyl, C₁₋₁₀-alkylene-C₃₋₁₀-cycloalkyl, C₁₋₁₀-alkylene-C₃₋₁₀-heterocycloalkyl, C₁₋₁₀-alkylene-(5-membered heteroaryl) and SO₂-C₁₋₁₀-alkyl, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, CN, OR¹¹, O-C₂₋₆-alkylene-OR¹¹, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, halogen, CO₂R¹¹, CONR¹¹R¹², CONR¹¹SO₂R¹¹, COR¹¹, SO_xR¹¹, SO₃H, SO₂NR¹¹R¹², NR¹¹COR¹¹, NR¹¹SO₂R¹¹, NR¹¹-CO-NR¹¹R¹², NR¹¹-SO₂-NR¹¹R¹², C₃₋₁₀-cycloalkyl, O-C₃₋₁₀-cycloalkyl, C₃₋₁₀-heterocycloalkyl, O-C₃₋₁₀-heterocycloalkyl and NR¹¹R¹²;

R² is R¹ or H;

or R¹ and R² when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, oxo, CN, OR¹¹, SO_xR¹¹, SO₃H, NR¹¹SO₂R¹¹, SO₂NR¹¹R¹², C₀₋₆-alkylene-CO₂R¹¹, CONR¹¹R¹², CONR¹¹SO₂R¹¹, COR¹¹, NR¹¹-CO-R¹¹, NR¹¹-CO-NR¹¹R¹², NR¹¹-SO₂-NR¹¹R¹², NR¹¹R¹², C₁₋₆-alkyl, halo-C₁₋₆-alkyl, hydroxy-C₁₋₆-alkyl, C₃₋₈-cycloalkyl, O-C₃₋₈-cycloalkyl, C₃₋₈-heterocycloalkyl and O-C₃₋₈-heterocycloalkyl,

substituents independently selected from the group consisting of fluoro, OH, oxo, C₁₋₄-alkyl and halo-C₁₋₄-alkyl;

R³² is independently selected from H, C₁₋₆-alkyl, halo-C₁₋₆-alkyl and C₃₋₆-cycloalkyl;


5 R⁴⁰ is C₃₋₁₀-cycloalkyl, which is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, O-C₁₋₆-alkyl, O-halo-C₁₋₆-alkyl, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, C₃₋₈-cycloalkyl and C₃₋₈-heterocycloalkyl;

R⁶¹ and R⁶² are independently selected from the group consisting of H, C₁₋₃-alkyl and halo-C₁₋₃-alkyl;

x and y is independently selected from 0, 1 and 2;

10 with the proviso that compound 5-(cyclopentylmethyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide is excluded and compounds of Formula (5), wherein R⁴ is OR⁴⁰ are excluded.

In one embodiment ~~a second aspect~~ of the present disclosure, there is provided a compound according to Formula (6) to Formula (9)



an enantiomer, diastereomer, tautomer, solvate, formulation and pharmaceutically acceptable salt thereof,

wherein

Q¹ is CO-NR⁵¹R⁵², CO-R⁵², CO₂R⁵¹, SO₂-NR⁵¹R⁵², SO₂-R⁵², NR⁵²CO-R⁵¹ or NR⁵²SO₂-R⁵¹;

20 Q² and Q³ are independently selected from N and CR⁵⁶;

R⁵¹ and R⁵² are independently selected from the group consisting of H, C₁₋₁₀-alkyl, C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl, C₀₋₁₀-alkylene-C₃₋₁₀-cycloalkyl, C₀₋₁₀-alkylene-C₃₋₁₀-heterocycloalkyl, C₀₋₁₀-alkylene 5 to 10-membered heteroaryl and C₀₋₁₀-alkylene-aryl, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or
 25 substituted with 1 to 7 substituents independently selected from the group consisting of oxo, CN, OR⁶¹, O-C₂₋₆-alkylene-OR⁶¹, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, halogen, CO₂R⁶¹, CONR⁶¹R⁶², CONR⁶¹SO₂R⁶², COR⁶¹, SO_xR⁶¹, SO₃H, SO₂NR⁶¹R⁶², NR⁶¹COR⁶¹, NR⁶¹SO₂R⁶¹, NR⁶¹-CO-NR⁶¹R⁶², NR⁶¹-SO₂-NR⁶¹R⁶², C₃₋₆-cycloalkyl, O-C₃₋₆-cycloalkyl, C₃₋₆-heterocycloalkyl, O-C₃₋₆-heterocycloalkyl and NR⁶¹R⁶²;

30 or R⁵¹ and R⁵² when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2

x is independently selected from 0, 1 and 2;

for use in the treatment or prophylaxis of a disease or disorder associated with the inhibition or activation of the ROR γ receptor.

In ~~another third~~ aspect of the present disclosure, there is provided the compound as disclosed above for use according to the first aspect as a medicament.

In ~~another a fourth~~ aspect of the present disclosure, there is provided the compound as disclosed above according to the first aspect for use in the treatment or prophylaxis of a disease or disorder associated with the inhibition or activation of the ROR γ receptor.

In ~~another fifth~~ aspect of the present disclosure, there is provided a pharmaceutical composition comprising a compound as disclosed above according to any of the first or second aspects and a pharmaceutically acceptable carrier or excipient.


In ~~another sixth~~ aspect of the present disclosure, there is provided a use of the compound according to the first aspect for the manufacture of a medicament for the treatment or prophylaxis of a disease or disorder associated with the inhibition or activation of the ROR γ receptor, wherein the disease is selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, lupus erythematosus, psoriasis, psoriatic arthritis, atopic eczema, inflammatory bowel diseases such as Crohn's disease, asthma, mucosal leishmaniasis, multiple sclerosis, systemic sclerosis, type 1 diabetes, Kawasaki disease, Hashimoto's thyroiditis, chronic graft-versus-host disease, acute graft-versus-host disease, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren's syndrome, scleroderma, ulcerative colitis, epidermal hyperplasia, glomerulonephritis, chronic obstructive pulmonary disease and amyotrophic lateral sclerosis.

Thus, the present disclosure provides carboxamide containing cyclic compounds as ROR γ modulators, which can be used for treating or preventing a disease or disorder associated with the inactivation or activation of the ROR γ receptor.

The present disclosure relates to a ROR γ modulator which is based on a cyclic scaffold for use in the treatment or prophylaxis of a disease or disorder associated with the inhibition or activation of ROR γ .


When treating the disease or disorder associated with the modulation of the ROR γ receptor, the activity of said receptor is preferably reduced.

Preferably, the disease or disorder is selected from the group consisting of autoimmune diseases. Autoimmune diseases comprise a group of diseases with a similar etiology of an overshooting immune response against endogenous targets resulting in chronic inflammation and physical disabilities or other severe symptoms. Autoimmune diseases comprise e.g. rheumatoid arthritis, ankylosing spondylitis, lupus erythematosus, psoriasis, psoriatic arthritis, atopic eczema, inflammatory bowel diseases such as Crohn's disease, asthma, mucosal leishmaniasis, multiple sclerosis, systemic sclerosis, type 1 diabetes, Kawasaki disease, Hashimoto's thyroiditis, chronic graft-versus-host disease, acute graft-versus-host disease, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjorgren's syndrome, scleroderma, ulcerative colitis, epidermal hyperplasia, glomerulonephritis, chronic obstructive pulmonary disease (COPD) and amyotrophic lateral sclerosis.



5

12. A compound according to Formula (6) to Formula (9)



an enantiomer, diastereomer, tautomer, solvate, formulation and pharmaceutically acceptable salt thereof,

10

wherein

Q^1 is $CO-NR^{51}R^{52}$, $CO-R^{52}$, CO_2R^{54} , $SO_2-NR^{51}R^{52}$, SO_2-R^{52} , $NR^{52}CO-R^{51}$ or $NR^{52}SO_2-R^{54}$;

Q^2 and Q^3 are independently selected from N and CR^{56} ;

R^{51} and R^{52} are independently selected from the group consisting of H, C_{4-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{0-10} -alkylene- C_{3-10} -cycloalkyl, C_{0-10} -alkylene- C_{3-10} -heterocycloalkyl, C_{0-10} -alkylene 5 to 10-membered heteroaryl and C_{0-10} -alkylene-aryl, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of

exo, CN, OR^{61} , $O-C_{2-6}$ -alkylene- OR^{61} , C_{4-6} -alkyl, halo- C_{4-6} -alkyl, halogen, CO_2R^{61} , $CONR^{61}R^{62}$, $CONR^{61}SO_2R^{62}$, COR^{61} , SO_xR^{61} , SO_3H , $SO_2NR^{61}R^{62}$, $NR^{61}COR^{61}$, $NR^{61}SO_2R^{61}$, $NR^{61}-CO-NR^{61}R^{62}$, $NR^{61}-SO_2-NR^{61}R^{62}$, C_{3-6} -cycloalkyl, $O-C_{3-6}$ -cycloalkyl, C_{3-6} -heterocycloalkyl, $O-C_{3-6}$ -heterocycloalkyl and $NR^{61}R^{62}$;

or R^{51} and R^{52} when taken together with the nitrogen to which they are attached complete a 3 to 8 membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms independently selected from the group consisting of O, S and N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, exo, CN, OR^{61} , SO_xR^{61} , SO_3H , $NR^{61}SO_2R^{61}$, $SO_2NR^{61}R^{62}$, CO_2R^{61} , $CONR^{61}R^{62}$, $CONR^{61}SO_2R^{62}$, COR^{61} , $NR^{61}-CO-R^{61}$, $NR^{61}-CO-NR^{61}R^{62}$, $NR^{61}-SO_2-NR^{61}R^{62}$, $NR^{61}R^{62}$, C_{4-6} -alkyl, halo- C_{4-6} -alkyl, hydroxy- C_{4-6} -alkyl, C_{3-6} -cycloalkyl, $O-C_{3-6}$ -cycloalkyl, C_{3-6} -heterocycloalkyl and $O-C_{3-6}$ -heterocycloalkyl;

R^{53} is a 6-10 membered mono- or bicyclic aryl or a 5-14 membered mono-, bi- or tricyclic heteroaryl containing 1 to 5 heteroatoms independently selected from the group consisting of N, O and S;

wherein aryl and heteroaryl are unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, CN, C_{4-6} -alkyl, C_{2-6} -alkenyl, C_{2-6} -alkynyl, halo- C_{4-6} -alkyl, OH, $O-C_{4-6}$ -alkyl, O -halo- C_{4-6} -alkyl, C_{0-6} -alkylene- C_{3-10} -cycloalkyl, C_{0-6} -alkylene- $O-C_{3-10}$ -cycloalkyl, C_{0-6} -alkylene- C_{3-10} -heterocycloalkyl, C_{0-6} -alkylene- $COOR^{81}$, C_{0-6} -alkylene- $C(O)R^{81}$, C_{0-6} -alkylene- $C(O)N(R^{81})_2$, C_{0-6} -alkylene- $N(R^{81})_2$, C_{0-6} -alkylene- $SO_2-N(R^{81})_2$, C_{0-6} -alkylene- SO_2-R^{81} , C_{0-6} -alkylene-(6-10-membered mono- or bicyclic aryl), and C_{0-6} -alkylene-(6-10-membered mono- or bicyclic heteroaryl);

wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl and heteroaryl are unsubstituted or substituted by 1 to 3 substituents independently selected from the group consisting of C_{4-6} -alkyl, halo- C_{4-6} -alkyl, halogen, OH, exo, $=N-OR^{82}$, $N(R^{81})_2$, $O-C_{4-6}$ -alkyl, O -halo- C_{4-6} -alkyl, $COOH$, $CON(R^{81})_2$, CN, $NR^{81}-COR^{81}$, C_{3-10} -cycloalkyl, C_{3-10} -heterocycloalkyl, 6-10-membered mono- or bicyclic aryl, and 6-10-membered mono- or bicyclic heteroaryl;

or wherein two adjacent substituents may complete a 4 to 8 membered saturated or partially unsaturated ring containing carbon atoms and optionally containing 1 to 3 members selected from the group consisting of O, S, SO, SO_2 and NR^{81} , wherein the ring is unsubstituted or substituted with 1 to 4r substituents independently selected

from the group consisting of halogen, oxo, $=N-OR^{82}$, OH, O-C₁₋₆-alkyl, O-halo-C₁₋₆-alkyl, C₁₋₆-alkyl, C₃₋₆-cycloalkyl and halo-C₁₋₆-alkyl;

R⁵⁴ is C₀₋₆-alkylene-R⁵⁷, C₃-cycloalkyl-R⁵⁷, O-C₀₋₅-alkylene-R⁵⁷, NR⁹⁴-C₀₋₅-alkylene-R⁵⁷ and SO_x-C₀₋₅-alkylene-R⁵⁷;

5 wherein alkylene is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, $=N-OR^{82}$, N(R⁸⁴)₂, O-C₁₋₆-alkyl, COOH, CON(R⁸⁴)₂, CN, NR⁸⁴-COR⁸⁴, C₃₋₆-cycloalkyl and C₃₋₆-heterocycloalkyl;

R⁵⁵ is independently selected from H, C₁₋₆-alkyl and C₃₋₆-cycloalkyl,

10 wherein alkyl and cycloalkyl is optionally substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, O-C₁₋₃-alkyl, O-halo-C₁₋₃-alkyl and C₃₋₆-cycloalkyl;

R⁵⁶ is independently selected from the group consisting of H, halogen, CN, C₁₋₆-alkyl, C₃₋₆-cycloalkyl, O-C₁₋₆-alkyl and CONHR⁶¹R⁶²;

15 wherein alkyl and cycloalkyl is unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of halogen, OH, oxo, O-C₁₋₃-alkyl, O-halo-C₁₋₃-alkyl and C₃₋₆-cycloalkyl;

R⁵⁷ is C₁₋₁₀-alkyl, C₃₋₁₀-cycloalkyl, C₃₋₁₀-heterocycloalkyl, 6-10-membered mono- or bicyclic aryl or 6-10-membered mono- or bicyclic heteroaryl,

20 wherein alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, oxo, O-C₁₋₆-alkyl, O-halo-C₁₋₆-alkyl, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, C₃₋₁₀-cycloalkyl and 5 to 10-membered heterocycloalkyl;

25 R⁶¹ and R⁸¹ are independently selected from the group consisting of H, C₁₋₆-alkyl, C₃₋₁₀-cycloalkyl, C₃₋₁₀-heterocycloalkyl, phenyl, 5-6-membered heteroaryl containing 1 to 4 heteroatoms independently selected from the group consisting of N, O and S

30 wherein alkyl, cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of C₁₋₆-alkyl, halo-C₁₋₆-alkyl, OH, O-C₁₋₆-alkyl, O-halo-C₁₋₆-alkyl, phenyl, 5 to 10-membered heteroaryl, halogen, NH₂, NH(C₁₋₆-alkyl), N(C₁₋₆-alkyl)₂, C₃₋₁₀-heterocycloalkyl, C₃₋₁₀-cycloalkyl, SO₂-C₁₋₃-alkyl, oxo, and CN;

wherein cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of C₁₋₆-alkyl, halo-C₁₋₆-alkyl, OH, O-C₁₋₆-alkyl, O-halo-C₁₋₆-alkyl, phenyl, 5 to 6-membered heteroaryl, halogen, NH₂, NH(C₁₋₆-alkyl), N(C₁₋₆-alkyl)₂ and C₃₋₁₀-cycloalkyl,

wherein phenyl and heteroaryl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of OH, O-C₁₋₆-alkyl, O-halo-C₁₋₆-alkyl, halogen, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, NH₂, NH(C₁₋₆-alkyl), N(C₁₋₆-alkyl)₂ and C₃₋₁₀-cycloalkyl;

5 R⁶² and R⁸² are independently selected from the group consisting of H, C₁₋₆-alkyl, halo-C₁₋₆-alkyl and C₃₋₁₀-cycloalkyl;

R⁹⁴ is H, C₁₋₆-alkyl, C₃₋₆-cycloalkyl or C₃₋₆-heterocycloalkyl;

10 wherein alkyl, cycloalkyl and heterocycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of OH, oxo, CN, halogen, O-C₁₋₆-alkyl, O-halo-C₁₋₆-alkyl, C₃₋₆-heterocycloalkyl and C₃₋₆-cycloalkyl;

x is independently selected from 0, 1 and 2;

for use in the treatment or prophylaxis of a disease or disorder associated with the inhibition or activation of the ROR_γ receptor.

15 13. The compound for use according to claim 12 wherein

Q¹ is selected from CO-NR⁶⁴R⁶²; and

Q² and Q³ is nitrogen.

14. The compound for use according to claim 12 wherein

20 Q¹ is CO-NR⁶⁴R⁶²; and

Q² and Q³ is CR⁶⁶.


15. The compound for use according to any of claims 12 to 14 wherein

25 R⁶⁴ is selected from the group consisting of H, C₁₋₁₀-alkyl, C₀₋₁₀-alkylene-C₃₋₁₀-cycloalkyl, C₀₋₁₀-alkylene-C₃₋₁₀-heterocycloalkyl, C₀₋₁₀-alkylene-5 to 10-membered heteroaryl and C₀₋₁₀-alkylene-aryl, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, CN, OR⁶⁴, O-C₂₋₆-alkylene-OR⁶⁴, C₁₋₆-alkyl, halo-C₁₋₆-alkyl, halogen, CO₂R⁶⁴, CONR⁶⁴R⁶², CONR⁶⁴SO₂R⁶², COR⁶⁴, SO_xR⁶⁴, SO₃H, SO₂NR⁶⁴R⁶², NR⁶⁴COR⁶⁴, NR⁶⁴SO₂R⁶⁴, NR⁶⁴CO-NR⁶⁴R⁶², NR⁶⁴SO₂NR⁶⁴R⁶², C₃₋₆-cycloalkyl, O-C₃₋₆-cycloalkyl, C₃₋₆-heterocycloalkyl, O-C₃₋₆-heterocycloalkyl and NR⁶⁴R⁶²;

30 R⁵² is selected from the group consisting of H, C₁₋₆-alkyl and halo-C₁₋₆-alkyl;

or R^{54} and R^{52} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from halogen, oxo, CN, OR^{61} , SO_xR^{61} , SO_3H , $NR^{61}SO_2R^{61}$, $SO_2NR^{61}R^{62}$, CO_2R^{61} , $CONR^{61}R^{62}$, $CONR^{61}SO_2R^{62}$, COR^{61} , $NR^{61}CO-R^{61}$, $NR^{61}CO-NR^{61}R^{62}$, $NR^{61}SO_2-NR^{61}R^{62}$, $NR^{61}R^{62}$, C_{1-6} -alkyl, halo- C_{1-6} -alkyl, hydroxy- C_{1-6} -alkyl, C_{3-6} -cycloalkyl, O- C_{3-6} -cycloalkyl, C_{3-6} -heterocycloalkyl and O- C_{3-6} -heterocycloalkyl.

16. The compound for use according to any of claims 12 to 15 wherein R^{53} is selected from



wherein

R^{83} is independently selected from halogen, C_{1-6} -alkyl, fluoro- C_{1-6} -alkyl, C_{1-4} -alkylene-OH, C_{1-4} -alkylene-CN, C_{1-4} -alkylene-O- C_{1-3} -alkyl, C_{1-4} -alkylene-O-fluoro- C_{1-3} -alkyl, O- C_{1-6} -alkyl, O-fluoro- C_{1-6} -alkyl, NH- C_{1-6} -alkyl, NH-fluoro- C_{1-6} -alkyl, C_{3-10} -cycloalkyl, $C(O)N(R^{87})_{27}$

wherein alkylene is unsubstituted or substituted with 1 to 3 substituents selected from F, and cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from F, C_{1-3} -alkyl and fluoro- C_{1-3} -alkyl;

R^{84} is selected from C_{1-4} -alkylene-OH, C_{1-4} -alkylene-O- C_{1-3} -alkyl, C_{1-4} -alkylene-O-fluoro- C_{1-3} -alkyl, C_{3-10} -cycloalkyl, $C(O)N(R^{87})_{27}$, $S(O_2)N(R^{87})_{27}$

wherein alkylene is unsubstituted or substituted with 1 to 3 substituents selected from F, and cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from F, C_{1-3} -alkyl and fluoro- C_{1-3} -alkyl;

R^{86} is selected from C_{1-6} -alkyl, fluoro- C_{1-6} -alkyl, $C(O)N(R^{87})_{27}$, $S(O_2)N(R^{87})_{27}$

R^{87} is independently selected from H, C_{1-6} -alkyl, fluoro- C_{1-6} -alkyl, C_{0-3} -alkylene- C_{1-6} -cycloalkyl, C_{1-6} -alkylene-OH, C_{1-6} -alkylene-O- C_{1-3} -alkyl, C_{1-6} -alkylene-CN, wherein alkylene and cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from F, C_{1-3} -alkyl and fluoro- C_{1-3} -alkyl,


and wherein two R^{87} when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2

heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from fluoro, oxo, C₁₋₄-alkyl and halo-C₁₋₄-alkyl;

R⁸⁸ is selected from H, C₁₋₃-alkyl and fluoro-C₁₋₃-alkyl;

R⁸⁹ is selected from H, F or OH;

5 X' is an annelated saturated heterocycle selected from the group consisting of



Y' is an annelated 5- or 6-membered carbocycle, an annelated 6-membered aryl or an annelated 6-membered heteroaryl containing 1 to 2 nitrogen atoms, wherein the carbocycle, aryl or heteroaryl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of fluoro, C₁₋₃-alkyl and fluoro-C₁₋₃-alkyl;

Z' is an annelated 6-membered cycle forming a heteroaryl containing 1 to 3 heteroatoms selected from the group consisting of O, S and N, wherein the heteroaryl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of fluoro, C₁₋₂-alkyl and fluoro-C₁₋₃-alkyl; and

m is selected from 1 to 4.

17. The compound for use according to any of claims 12 to 16 wherein

R⁶⁴ is selected from C₄-alkylene-R⁶⁷ and SO₂-R⁶⁷;

wherein alkylene is unsubstituted or substituted once with OH, oxo, O-C₁₋₆-alkyl, CN C₃₋₆-cycloalkyl or fluoro or twice with fluoro;

R⁶⁷ is selected from C₁₋₁₀-alkyl, C₃₋₁₀-cycloalkyl, C₃₋₁₀-heterocycloalkyl, 6-10-membered mono- or bicyclic aryl and 6-10-membered mono- or bicyclic heteroaryl;

wherein alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, oxo, O-C₁₋₃-alkyl, O-halo-C₁₋₃-alkyl, C₁₋₃-alkyl, halo-C₁₋₃-alkyl, cycloalkyl and heterocycloalkyl.

1248. The compound according to any of claims 1 to 11 for use as a medicament.

1349. The compound according to any of claims 1 to 11 for use in the treatment or prophylaxis of a disease or disorder associated with the inhibition or activation of the ROR γ receptor.

1420. The compound for use according to claim 1349, wherein the disease is selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, lupus erythematosus, psoriasis, psoriatic arthritis, atopic eczema, inflammatory bowel diseases such as Crohn's disease, asthma, mucosal leishmaniasis, multiple sclerosis, systemic sclerosis, type 1 diabetes, Kawasaki disease, Hashimoto's thyroiditis, chronic graft-versus-host disease, acute graft-versus-host disease, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren's syndrome, scleroderma, ulcerative colitis, epidermal hyperplasia, glomerulonephritis, chronic obstructive pulmonary disease and amyotrophic lateral sclerosis.

1524. A pharmaceutical composition comprising a compound according to any of claims 1 to 1147 and a pharmaceutically acceptable carrier or excipient.

~~22. The compound for use according to any of claims 12 to 17, wherein the disease or disorder is selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, lupus erythematosus, psoriasis, psoriatic arthritis, atopic eczema, inflammatory bowel diseases such as Crohn's disease, asthma, mucosal leishmaniasis, multiple sclerosis, systemic sclerosis, type 1 diabetes, Kawasaki disease, Hashimoto's thyroiditis, chronic graft-versus-host disease, acute graft-versus-host disease, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren's syndrome, scleroderma, ulcerative colitis, epidermal hyperplasia, glomerulonephritis, chronic obstructive pulmonary disease and amyotrophic lateral sclerosis.~~

1623. Use of the compound according to any of claims 1 to 11 for the manufacture of a medicament for the treatment or prophylaxis of a disease or disorder associated with the inhibition or activation of the ROR γ receptor.

~~24. Use according to claim 23, wherein the disease is selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, lupus erythematosus, psoriasis, psoriatic arthritis, atopic eczema, inflammatory bowel diseases such as Crohn's disease, asthma, mucosal leishmaniasis, multiple sclerosis, systemic sclerosis, type 1 diabetes, Kawasaki disease, Hashimoto's thyroiditis, chronic graft-versus-host disease, acute graft-versus-host disease, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren's syndrome, scleroderma, ulcerative colitis, epidermal hyperplasia, glomerulonephritis, chronic obstructive pulmonary disease and amyotrophic lateral sclerosis.~~